ArticleOncology letters2016
Derived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Pooled it
- GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma.Cancer biology & medicine · 2025Article
- Increased Pre-Operative Lung Immune Prognostic Index Score Is a Prognostic Factor in Cases of Pathological T3 Renal Cell Carcinoma.Current oncology (Toronto, Ont.) · 2025Article
- The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease.Cancers · 2024Article
- Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Review
- Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival.Langenbeck's archives of surgery · 2023Article
- CXCR2 Antagonist RIST4721 Acts as a Potent Chemotaxis Inhibitor of Mature Neutrophils Derived from Ex Vivo-Cultured Mouse Bone Marrow.Biomedicines · 2023Article
- The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective.Frontiers in immunology · 2023Review
- Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective.Cancers · 2022Review
- Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection.Frontiers in surgery · 2022Article
- Prognostic significance of the systemic immune inflammation index in patients with metastatic and unresectable pancreatic cancer.Frontiers in surgery · 2022Article
- Neutrophil in the Pancreatic Tumor Microenvironment.Biomolecules · 2021Review
- Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma.Journal of gastrointestinal cancer · 2021Article
- Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth.Nature communications · 2021Article
- The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.Current oncology (Toronto, Ont.) · 2020Article
- The Immune Microenvironment in Pancreatic Cancer.International journal of molecular sciences · 2020Review
- NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score.Cancer management and research · 2020Article
- Neutrophils in the Tumor Microenvironment.Advances in experimental medicine and biology · 2020Review
- Novel Biomarkers for Personalized Cancer Immunotherapy.Cancers · 2019Review
- Tumor-Associated Neutrophils in Cancer: Going Pro.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As gemcitabine is a key anti-tumor agent for unresectable pancreatic ductal adenocarcinoma (PDAC), it is important to predict the outcomes of gemcitabine chemotherapy. The present study aimed to confirm whether the derived neutrophil-to-lymphocyte ratio (dNLR) is able to predict chemotherapy outcomes. To elucidate the role of dNLR in patients that underwent chemotherapy, the current study evaluated clinicopathological variables in 31 patients with unresectable PDAC treated with gemcitabine. The correlation between clinicopathological variables, and progression-free survival (PFS) and overall survival (OS) time were investigated. Univariate analysis revealed that there were no significant differences in PFS and OS as a function of age (<65 vs. ≥65 years), gender, tumor location (pancreas head vs. body/tail), tumor diameter (<23 vs. ≥23 mm) or serum carbohydrate antigen 19-9 concentration level (<3,800 vs. ≥3,800 U/ml). However, disease stage (locally advanced vs. metastatic) and the dNLR (<2.5 vs. ≥2.5) significantly affected PFS and OS. Multivariate analysis subsequently revealed that a dNLR of ≥2.5 was an independent prognostic factor for poor PFS (P=0.003) and OS (P=0.026). In conclusion, data from the present study suggests that the pre-treatment dNLR is an independent prognostic factor to predict PFS and OS in patients with unresectable PDAC treated with gemcitabine. This indicates that dNLR has a potential role in stratifying patients that may benefit from gemcitabine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.